The department of health (DoH) in Abu Dhabi — one of the seven emirates that make up the United Arab…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Most individuals with spinal muscular atrophy (SMA) type 2 experience improvements in physical abilities within a year after starting…
Twenty-six children were diagnosed with spinal muscular atrophy (SMA) in Russia through a 2022 pilot program, out of nearly…
Levels of certain molecules in cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — may…
A novel monitoring tool called MScanFit may be a reliable way to assess the health of nerve and muscle cells…
Serious side effects that can cause or prolong hospital stays occurred frequently among children with spinal muscular atrophy (SMA)…
Six unusual cases of children with spinal muscular atrophy (SMA) caused by sequence variants, rather than the more common…
The case of a boy with spinal muscular atrophy (SMA) who had severe hyperlordosis — when the lower part…
Without treatment, most people with spinal muscular atrophy (SMA) who have four copies of the “backup” SMN2 gene will…
In children with spinal muscular atrophy (SMA) who have a less-than-optimal response to the gene therapy Zolgensma…